Redwood Pharma AB
Redwood Pharma AB engages in the development of ophthalmic drugs for medical needs in Sweden. Its lead development product is RP101, an eye drop that treats severe chronic dry eye disease in post-menopausal women; and RP501, a next generation smart hydrogel medical device for the treatment of mild dry eye. The company was founded in 2012 and is headquartered in Stockholm, Sweden.
Market Cap & Net Worth: Redwood Pharma AB (REDW)
Redwood Pharma AB (ST:REDW) has a market capitalization of $280.40K (Skr3.15 Million) as of March 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #38677 globally and #642 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Redwood Pharma AB's stock price Skr1.19 by its total outstanding shares 2654500 (2.65 Million).
Redwood Pharma AB Market Cap History: 2016 to 2024
Redwood Pharma AB's market capitalization history from 2016 to 2024. Data shows change from $459.74K to $280.40K (-4.04% CAGR).
Redwood Pharma AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Redwood Pharma AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of REDW by Market Capitalization
Companies near Redwood Pharma AB in the global market cap rankings as of March 19, 2026.
Key companies related to Redwood Pharma AB by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Redwood Pharma AB Historical Marketcap From 2016 to 2024
Between 2016 and today, Redwood Pharma AB's market cap moved from $459.74K to $ 280.40K, with a yearly change of -4.04%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2024 | Skr280.40K | +2421.28% |
| 2023 | Skr11.12K | -74.59% |
| 2022 | Skr43.78K | -75.86% |
| 2021 | Skr181.33K | -63.95% |
| 2020 | Skr502.97K | -32.00% |
| 2019 | Skr739.67K | +62.27% |
| 2018 | Skr455.81K | +41.48% |
| 2017 | Skr322.17K | -29.92% |
| 2016 | Skr459.74K | -- |
End of Day Market Cap According to Different Sources
On Nov 20th, 2025 the market cap of Redwood Pharma AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $280.40K USD |
| MoneyControl | $280.40K USD |
| MarketWatch | $280.40K USD |
| marketcap.company | $280.40K USD |
| Reuters | $280.40K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.